4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid
4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Basic information
- Product Name:
- 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid
- Synonyms:
-
- AGN 193109
- 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]benzoic Acid
- CD 3106
- 4-((5,5-Dimethyl-8-p-tolyl-5,6-dihydronaphthalen-2-yl)ethynyl)benzoic acid
- 4-{[5,5-diMethyl-8-(4-Methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid
- AGN 193109 SodiuM Salt
- Benzoic acid, 4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-
- AGN193109,Autophagy,Inhibitor,Retinoic acid receptors,Retinoid X receptors,RAR/RXR,AGN 193109,AGN-193109,inhibit
- CAS:
- 171746-21-7
- MF:
- C28H24O2
- MW:
- 392.49
- Product Categories:
-
- Aromatics Compounds
- Aromatics
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Mol File:
- 171746-21-7.mol
4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Chemical Properties
- Melting point:
- 246-255?C
- Boiling point:
- 564.5±50.0 °C(Predicted)
- Density
- 1.21±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- solubility
- Chloroform (Slightly, Heated), DMSO (Slightly, Sonicated)
- form
- Solid
- pka
- 4.08±0.10(Predicted)
- color
- Off-White to Pale Yellow
- Stability:
- Hygroscopic
4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Usage And Synthesis
Chemical Properties
Off-White Solid
Uses
As a retinoic acid receptor (RAR) antagonist, 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid can be used for treating chemotherapy and radiation therapy side effects.
Biological Activity
AGN 193109 is an orally active retinoic acid receptor (RAR) antagonist th at targets all three RAR subtypes with higher affinity (RARα/β/γ Kd = 2 nM) than all-trans retinoic acid/ATRA (RARα/β/γ Kd = 9/12/19 nM). AGN 193109 potently antagonizes against ATRA-induced transcription in RARα, RARβ, and RARγ transfected CV-1 cells (by 85%, 62%, and 100%, respectively, by equal molar AGN 193109 against ATRA). AGN 193109 is also widely employeed to block RAR-mediated physiological and pathalogical processes in mice and rats in vivo via oral (1-10 mg/kg) or topical (0.3-36 μmol/kg) administration.
in vivo
AGN 193109 (1.15 μmol/kg) does not causes overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA. AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment[3].
storage
Store at -20°C
4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acidSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 13816613772
- huahero21@sina.com
- Tel
- 052386810091
- zcwy9518@yeah.net